With nearly $100 million in new investments since last year, the San Francisco-based informatics firm looks to ramp up its precision oncology partnerships.
Vikor has invested an undisclosed amount to help the startup commercialize a direct-to-consumer service that includes genomic risk testing and liquid biopsy cancer screening.
With its liquid biopsy test FDA approved and monitoring and screening offerings poised for launch, the firm is turning its attention to tumor tissue testing.
The researchers identified molecular subtypes of head and neck cancer that could be susceptible to CDK inhibitor, anti-EGFR antibody, or immunotherapy treatments.
A multi-ancestry genome-wide association study meta-analysis uncovered 86 genetic loci associated with prostate cancer risk that researchers bundled into a genetic risk score.
